AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
ARS Pharmaceuticals, Inc (NASDAQ:SPRY)
9.65 USD
-0.250 2.525%Sponsored Reports
Loading...
| Previous Close (in USD) | 9.9 |
|---|---|
| Change | -0.250 2.525% |
| 52 W H/L (in USD) | 11.270/2.550 |
| EBITDA (in USD) | -61.935M |
| PE Ratio | -- |
| Volume | 2277986 |
| Diluted Eps TTM | -0.52 |
| Total Assets (in USD) | 233.188M |
|---|---|
| Total Liabilities (in USD) | 2.428M |
| Revenue TTM (in USD) | 0.01M |
| Cash (in USD) | 70.971M |
| Market Cap (in USD) | 870.120 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 1.316M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Silverback Therapeutics Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Employees: 24
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, Pres, CEO & Director | 1966 |
| 2. | Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer | 1968 |
| 3. | Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer | NA |
| 4. | Ms. Kathleen D. Scott CPA | Chief Financial Officer | NA |
| 5. | Mr. Brian T. Dorsey M.S. | SVP of Operations & Project Management | NA |
| 6. | Mr. Daniel Relovsky | Sr. VP of Marketing | NA |
| 7. | Mr. Harris Kaplan M.B.A., MBA | Exec. VP of Commercial Strategy | 1952 |
| 8. | Mr. Eric Karas | Chief Commercial Officer | 1972 |
| 9. | Mr. Justin Chakma | Chief Bus. Officer & Sec. | 1989 |
| 10. | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, President, CEO & Director | 1966 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -54.365M | -34.682M | -20.243M | -1.065M | -23.967M |
| Minority Interest | - | - | - | - | - |
| Net Income | -54.365M | -33.988M | -20.243M | -1.065M | -23.967M |
| Selling General Administrative | 47.284M | 18.456M | 4.687M | 4.234M | - |
| Gross Profit | -0.043M | -16.004M | -14.767M | 3.765M | -1.546M |
| Reconciled Depreciation | 0.36M | 0.319M | 0.006M | 0.006M | - |
| Ebit | -67.52M | -35.516M | -19.454M | -0.469M | -24.067M |
| Ebitda | -67.447M | -35.057M | -19.448M | -0.463M | -22.521M |
| Depreciation And Amortization | 0.073M | 0.459M | 0.006M | 0.006M | 1.546M |
| Operating Income | -67.52M | -35.516M | -19.454M | -0.469M | -24.067M |
| Other Operating Expenses | 67.55M | 36.832M | 24.96M | 18.304M | 24.067M |
| Interest Expense | - | 0.834M | 0.106M | 0.029M | - |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | - | -0.694M | 0.789M | 0.596M | - |
| Total Revenue | 0.03M | 1.316M | 5.506M | 17.835M | - |
| Total Operating Expenses | 67.477M | 36.832M | 24.96M | 18.304M | 22.521M |
| Cost Of Revenue | 0.073M | 17.32M | 20.273M | 14.07M | 1.546M |
| Total Other Income Expense Net | 13.155M | 0.834M | -0.789M | -0.596M | 0.1M |
| Net Income From Continuing Ops | -61.626M | -34.682M | -20.243M | -1.065M | - |
| Net Income Applicable To Common Shares | - | -34.682M | -20.243M | -1.065M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 233.188M | 281.435M | 61.446M | 26.407M | 15.647M |
| Intangible Assets | 0.617M | - | - | - | - |
| Other Current Assets | 2.408M | 3.319M | 7.447M | 1.477M | 0.552M |
| Total Liab | 2.428M | 8.549M | 92.715M | 40.459M | 21.25M |
| Total Stockholder Equity | 230.76M | 272.886M | -31.269M | -14.052M | -5.603M |
| Other Current Liab | 1.391M | 3.272M | 1.321M | 0.915M | 2.112M |
| Common Stock | 0.01M | 0.009M | 0.257M | 0.223M | - |
| Capital Stock | 0.01M | 0.009M | 0.257M | 0.223M | - |
| Retained Earnings | -131.303M | -76.938M | -42.256M | -22.013M | -63.787M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 2.961M | 0.023M | 0.002M | - |
| Cash | 70.971M | 210.518M | 60.063M | 24.521M | 9.976M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.391M | 5.444M | 8.187M | 8.21M | 17.926M |
| Current Deferred Revenue | 0.004M | 0.283M | 1.457M | 3.518M | - |
| Net Debt | -70.697M | -210.037M | -51.03M | -14.503M | 5.644M |
| Short Term Debt | 0.237M | 0.23M | 3.623M | 2.558M | 12.296M |
| Short Long Term Debt | - | - | 3.479M | 2.558M | - |
| Short Long Term Debt Total | 0.274M | 0.481M | 9.033M | 10.018M | 15.62M |
| Other Stockholder Equity | 128.816M | 67.973M | 10.73M | 7.738M | 5.01M |
| Property Plant Equipment | - | 0.329M | 0.693M | 0.023M | - |
| Total Current Assets | 231.563M | 277.7M | 60.73M | 26.382M | 10.528M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 157.389M | 63.863M | - | - | - |
| Net Receivables | 0.795M | 1.009M | 0.001M | 0.384M | - |
| Long Term Debt | - | - | 4.93M | 7.46M | - |
| Inventory | - | -1.009M | -6.781M | - | - |
| Accounts Payable | 0.759M | 1.659M | 1.786M | 1.219M | 3.518M |
| Accumulated Other Comprehensive Income | 0.049M | 0.407M | -0.326M | - | - |
| Non Currrent Assets Other | 0.184M | 2.961M | -64.757M | 0.002M | - |
| Non Current Assets Total | 1.625M | 3.735M | 0.716M | 0.025M | 5.119M |
| Capital Lease Obligations | 0.274M | 0.481M | 0.624M | 0M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -113.345M | 63.473M | -0.055M | 0M | - |
| Total Cashflows From Investing Activities | - | -0.199M | -0.055M | -0.055M | - |
| Total Cash From Financing Activities | 6.899M | 190.732M | 53.158M | 5.099M | 8.61M |
| Net Income | -54.365M | -34.682M | -20.243M | -1.065M | -23.967M |
| Change In Cash | -139.547M | 150.455M | 35.542M | 14.17M | -10.184M |
| Begin Period Cash Flow | 210.518M | 60.063M | 24.521M | 10.351M | 20.16M |
| End Period Cash Flow | 70.971M | 210.518M | 60.063M | 24.521M | 9.976M |
| Total Cash From Operating Activities | -59.266M | -40.078M | -17.561M | 9.071M | -18.898M |
| Depreciation | 0.073M | 0.319M | 0.006M | 0.006M | 1.546M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | 0.57M | - | - | - |
| Other Cashflows From Financing Activities | 6.899M | 198.843M | 53.158M | -403.407M | -0.096M |
| Capital Expenditures | 0.175M | 0.199M | 0.055M | 0.917M | 0.096M |
| Change In Working Capital | -7.331M | -12.754M | -0.356M | 6.464M | 3.3M |
| Other Non Cash Items | -9.655M | 1.196M | 0.207M | 0.121M | -0.699M |
| Free Cash Flow | -59.441M | -40.277M | -17.616M | 8.154M | -18.994M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Franklin Biotechnology Discv A(acc)USD | 2 years ago | 1929794 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1861007 |
| 3. | Fidelity Select Biotechnology | 2 years ago | 1082956 |
| 4. | Franklin Biotechnology Discovery A | 2 years ago | 1020789 |
| 5. | SPDR® S&P Biotech ETF | 2 years ago | 866231 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 768665 |
| 7. | iShares Russell 2000 ETF | 2 years ago | 569158 |
| 8. | Invesco Dorsey Wright SmallCap Momt ETF | 2 years ago | 405893 |
| 9. | APO Medical Opportunities R | 2 years ago | 333694 |
| 10. | iShares Biotechnology ETF | 2 years ago | 309365 |
| 11. | Fidelity Extended Market Index | 2 years ago | 293266 |
| 12. | Fidelity Small Cap Index | 2 years ago | 251371 |
| 13. | Schwab US Small-Cap ETF™ | 2 years ago | 237759 |
| 14. | Royce Smaller-Companies Growth Svc | 2 years ago | 217000 |
| 15. | Royce Micro-Cap Invmt | 2 years ago | 203124 |
| 16. | iShares Russell 2000 Value ETF | 2 years ago | 187004 |
| 17. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 166600 |
| 18. | Protea Sectoral Hlthcare Opps P USD Acc | 2 years ago | 133428 |
| 19. | BlackRock Extended Mkt Composite | 2 years ago | 118689 |
| 20. | BlackRock Extended Equity Market K | 2 years ago | 102959 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 2 years ago | 9459678 |
| 2. | Orbimed Advisors, LLC | 2 years ago | 9240887 |
| 3. | Franklin Resources Inc | 2 years ago | 4098497 |
| 4. | SR ONE CAPITAL MANAGEMENT, LP | 2 years ago | 4012903 |
| 5. | Nantahala Capital Management, LLC | 2 years ago | 3193008 |
| 6. | K2 PRINCIPAL FUND LP | 2 years ago | 3054333 |
| 7. | Vanguard Group Inc | 2 years ago | 2886455 |
| 8. | BlackRock Inc | 2 years ago | 2637549 |
| 9. | Nextech Invest AG | 2 years ago | 1910029 |
| 10. | FMR Inc | 2 years ago | 1202315 |
| 11. | Sio Capital Management, LLC | 2 years ago | 1105911 |
| 12. | Perceptive Advisors LLC | 2 years ago | 867319 |
| 13. | Geode Capital Management, LLC | 2 years ago | 864869 |
| 14. | Woodline Partners LP | 2 years ago | 661414 |
| 15. | Rubric Capital Management LP | 2 years ago | 639203 |
| 16. | State Street Corporation | 2 years ago | 576980 |
| 17. | Royce & Associates, LP | 2 years ago | 473700 |
| 18. | Charles Schwab Investment Management Inc | 2 years ago | 345295 |
| 19. | Dafna Capital Management LLC | 2 years ago | 311169 |
| 20. | Goldman Sachs Group Inc | 2 years ago | 282202 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...